Cost‐Effectiveness Analysis of Omalizumab Combined With Standard of Care in Treating Moderate to Severe Asthma Children in China
Adding omalizumab to SOC treatment in pediatric moderate to severe asthma patients would be a cost-effective choice under the current medical insurance reimbursement policy in China.
Authors
- Wang Cao (ORCID: https://orcid.org/0000-0003-3967-9244)
- Yuncui Yu (ORCID: https://orcid.org/0000-0002-1559-9752)
- Alec Morton (ORCID: https://orcid.org/0000-0003-3803-8517)
- Peng Guo (ORCID: https://orcid.org/0000-0002-5435-5523)
- Yue Xiao (ORCID: https://orcid.org/0000-0002-2127-8947)
- Huijie Huang (ORCID: https://orcid.org/0000-0002-1286-2252)
- Wei Jing (ORCID: https://orcid.org/0000-0002-8794-7832)
Institutions
- National University of Singapore (SG)
- University of Strathclyde (GB)
- Capital Medical University (CN)
- Development Research Center (CN)
- Beijing Children’s Hospital (CN)
- National University Health System (SG)
Publication Details
- Journal
- Pediatric Pulmonology
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1002/ppul.71066
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00